Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Vertex Pharmaceuticals Incorporated
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Males and females between 18 and 70 years old
Detectable plasma hepatitis C virus (HCV) ribonucleic acid (RNA) greater than or equal to (\>=) 10,000 international units per milliliter (IU/mL)
Must have chronic hepatitis C (genotype 1) and have already received at least one prior course of pegylated interferon alfa 2a with ribavirin
Cannot also be infected with Human Immunodeficiency Virus or hepatitis B
Must be judged to be in general good health and able to receive Pegasys® and Copegus®
No drug or alcohol abuse in the last year
Must agree to use two effective methods of birth control during the study and for 6 months after you stop taking study medication. One of the methods needs to be a 'barrier' method (condom or diaphragm)
If you are a woman, you cannot be in this study if you are pregnant or nursing
You may not be if
Participation in any clinical trial of a HCV protease inhibitor of any duration
Prior response to therapy and failure to achieve SVR which was due to treatment non-compliance
Any other cause of significant liver disease in addition to hepatitis C; this may include but is not limited to, hepatitis B, drug or alcohol-related cirrhosis, autoimmune hepatitis, hemochromatosis, Wilson's disease, nonalcoholic steatohepatitis, or primary biliary cirrhosis
Diagnosed or suspected hepatocellular carcinoma
History of or current evidence of decompensated liver disease
Participation in any clinical trial of an investigational drug within 90 days before drug administration or participation in more than 2 drug studies in the last 12 months (exclusive of the current study)
